Transfer pricing tested party selection and major corporate deductions were largely upheld, with limited claims remanded for verification.

Transfer pricing under TNMM should ordinarily use the least complex entity as the tested party where reliable comparables are available; on the facts, overseas associated enterprises were accepted on that basis and recomputation was directed. ESOP discount was treated as ascertained employee compensation allowable as business expenditure, and section 40(a)(ia) was held inapplicable. Contributions to the healthcare society and science foundation were allowed as business deductions. The section 14A disallowance, and the corresponding MAT adjustment under section 115JB, were deleted because the Assessing Officer had not recorded the requisite dissatisfaction and the disallowance could not exceed exempt income. Deductions under sections 80IB and 80IC were upheld, while the section 35(2AB), Drug Price Control Order and exchange fluctuation claims were remanded for verification; write-back of provision for diminution in investment value was allowed.

---

---

Issues: (i) whether overseas associated enterprises could be accepted as the tested party for transfer pricing analysis; (ii) whether deferred employee compensation under the ESOP scheme was allowable and whether section 40(a)(ia) applied; (iii) whether contributions to the healthcare society and science foundation were deductible; (iv) whether disallowance under section 14A and the corresponding adjustment under section 115JB were sustainable; (v) whether deduction under sections 80IB and 80IC could be denied for the eligible units; (vi) whether the claims relating to section 35(2AB), the Drug Price Control Order demand, exchange fluctuation on ECBs and write-back of provision for diminution in investment value were to be allowed or remanded.

Issue (i): whether overseas associated enterprises could be accepted as the tested party for transfer pricing analysis.

Analysis: The transfer pricing exercise was held to begin with selection of the tested party, which should ordinarily be the least complex participant for whom reliable comparables and data are available. The overseas associated enterprises were found to be less complex on the functional, asset and risk profile. The Advance Pricing Agreement entered with the tax administration, though for a later year, was treated as having persuasive value because the functions, assets, risks and methodology were similar. The earlier year decision in the assessee's own case was distinguished on facts because reliable regional and country-wise comparable data were available in the present year.

Conclusion: Overseas associated enterprises were accepted as the tested party, and the transfer pricing issue was remitted for recomputation on that basis in favour of the assessee.

Issue (ii): whether deferred employee compensation under the ESOP scheme was allowable and whether section 40(a)(ia) applied.

Analysis: The ESOP discount represented employee compensation for services rendered and was held to be an ascertained business expenditure, not a contingent liability. The decision of the Special Bench in Biocon and the Madras High Court in PVP Ventures were followed. No provision requiring deduction of tax at source on this payment was shown to apply.

Conclusion: The ESOP expenditure was held allowable under section 37(1), and the disallowance under section 40(a)(ia) was rejected in favour of the assessee.

Issue (iii): whether contributions to the healthcare society and science foundation were deductible.

Analysis: The contributions were found to have been made in the course of business and the issue was covered by earlier orders in the assessee's own case. No basis for tax deduction at source on the contribution was established.

Conclusion: The contributions were allowed as deduction in favour of the assessee.

Issue (iv): whether disallowance under section 14A and the corresponding adjustment under section 115JB were sustainable.

Analysis: The assessee had already made a substantial suo motu disallowance in excess of the exempt dividend income. The Assessing Officer had not recorded the requisite dissatisfaction with the assessee's claim before invoking Rule 8D. The disallowance was also held not to be capable of exceeding the exempt income. Since the section 14A adjustment failed in the normal computation, the parallel addition under section 115JB also could not survive.

Conclusion: The disallowance under section 14A and the consequential adjustment under section 115JB were deleted in favour of the assessee.

Issue (v): whether deduction under sections 80IB and 80IC could be denied for the eligible units.

Analysis: The deduction in the initial years had already been examined and accepted for the existing eligible units, and there was no material change in facts or law. The accounts maintained on the ERP system were held sufficient to ascertain unit-wise profits, and the statutory provisions did not mandate separate books in the narrow sense suggested by the Revenue. Allocation of common expenses on a rational and consistent basis was upheld. The objections based on inter-unit transfer valuation and alleged non-filing of balance sheets with Form 10CCB were rejected, especially where the relevant statements were available before final assessment.

Conclusion: The deduction under sections 80IB and 80IC was allowed in favour of the assessee.

Issue (vi): whether the claims relating to section 35(2AB), the Drug Price Control Order demand, exchange fluctuation on ECBs and write-back of provision for diminution in investment value were to be allowed or remanded.

Analysis: The claim under section 35(2AB) required verification of the underlying facts and was remitted. The Drug Price Control Order demand was held prima facie allowable, but verification was directed. The exchange fluctuation and related hedging claims were also sent back for verification to determine whether they were revenue items or capital cost forming part of actual cost. The reversal of provision for diminution in investment value was linked to a provision already disallowed in the earlier year and was found not to attract a second taxation in the current year.

Conclusion: The section 35(2AB), Drug Price Control Order and exchange fluctuation claims were remanded for verification, while the write-back of provision for diminution in investment value was allowed in favour of the assessee.

Final Conclusion: The appeal resulted in substantial relief to the assessee: the transfer pricing objection on tested party selection succeeded, the major corporate tax disallowances were deleted, the deduction under sections 80IB and 80IC was upheld, and only limited claims were remanded for factual verification.

Ratio Decidendi: For transfer pricing under TNMM, the tested party should ordinarily be the least complex entity for which reliable comparable data is available, and where a consistent, factually similar APA and established accounts support that selection, it should be respected unless contrary facts are shown.

---